Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis

Biomed Pharmacother. 2021 Nov:143:112115. doi: 10.1016/j.biopha.2021.112115. Epub 2021 Sep 3.

Abstract

Renal fibrosis is a failed wound-healing process of the kidney tissue after chronic, sustained injury, which is a common pathway and pathological marker of virtually every type of chronic kidney disease (CKD), regardless of cause. However, there is a lack of effective treatment specifically targeting against renal fibrosis per se to date. The main pathological feature of renal fibrosis is the massive activation and proliferation of renal fibroblasts and the excessive synthesis and secretion of extracellular matrix (ECM) deposited in the renal interstitium, leading to structural damage, impairment of renal function, and eventually end-stage renal disease. In this review, we summarize recent advancements regarding the participation and interaction of many types of kidney residents and infiltrated cells during renal fibrosis, attempt to comprehensively discuss the mechanism of renal fibrosis from the cellular level and conclude by highlighting novel therapeutic targets and approaches for development of new treatments for patients with renal fibrosis.

Keywords: Chronic kidney disease; Inflammation; Renal fibrosis; Renal tubular epithelial cells; Therapeutic strategy.

Publication types

  • Review

MeSH terms

  • Animals
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / metabolism*
  • Extracellular Matrix / pathology
  • Fibrosis
  • Humans
  • Kidney / drug effects
  • Kidney / metabolism*
  • Kidney / pathology
  • Kidney Diseases / drug therapy
  • Kidney Diseases / metabolism*
  • Kidney Diseases / pathology
  • Molecular Targeted Therapy
  • Renal Agents / therapeutic use
  • Signal Transduction

Substances

  • Renal Agents